Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement, defined by its clinical features and the presence in the blood of antibodies against one or more components of cell nuclei. Neurological and psychiatric complications of SLE include seizures, psychosis, cerebrovascular disease, cognitive dysfunction and headache, described in up to 75% of patients. In general terms, any part of the nervous system may be involved, however, central nervous system (CNS) complications are of relevance because they can significantly affect prognosis and mortality.

Different pathogenetic mechanisms have been claimed to play a relevant role in CNS complications of SLE such as vasculitis, antibodies against brain tissues, deposition of immunocomplex, overproduction of cytokines, thrombosis, and hemorrhage.

Myelopathy is one of 19 possible syndromes described by the American College of Rheumatology, with transverse myelitis (TM) being a rare but serious neurologic complication. It presents as a rapidly progressive motor, sensory and autonomic dysfunction, with uncertain pathophysiology, whose prevalence seems to be in the region of 1-2% among SLE patients. Since the initial description of the first nine cases in 1968, SLE-related TM is now a well-known clinical entity and a number of authors pointed out the close relationships with anti-phospholipid antibodies (aPL) syndrome. In fact, from 55% to 64% of SLE-related TM present high levels of aPL, which is higher than that reported in the general SLE population (30-50%). Different authors, therefore, speculated that the pathogenesis of TM may be related to a vascular thrombosis or to a direct interaction between aPL and membrane phospholipids at the spinal cord level.

A rare variant of the SLE-related myelopathy is longitudinal myelitis (LM), which is defined by the continuous involvement of more than four spinal cord segments. In fact, one to four spinal segments are generally involved in SLE-related TM. Longitudinal myelitis needs to be promptly diagnosed and recognized because it is characterized by an acute catastrophic onset and an unfavorable prognosis, and a closer association with aPL syndrome has been suggested when compared to TM.

Here, we describe a patient presenting with LM and peripheral neuropathy as early manifestations of SLE, with negative aPL and a favorable outcome. Clinical, electrophysiological and radiological features at the onset and during the follow-up are discussed.

**CASE REPORT**

**Patient history**

A 63-year-old woman was admitted to our Department for acute/sub-acute onset of fever, severe neck pain, weakness predominantly affecting both legs and the left arm, left-sided tingling sensations and sphincter disturbances (acute urinary retention, ileus paralyticus). The neurological examination revealed paraparesis and left arm paresis with dystonic posturing of the left hand and left foot. Reflexes were brisk at the four limbs and prevalent at the left side. She presented a bilateral Babinski. All-sensory modalities were lost below D6 level. Consciousness was preserved and the mental state was normal. Cranial nerves were normal.

The patient had a childhood history of rheumatic fever and an eight-year history of bilateral glaucoma. Since the age of 40 she referred migratory arthralgias involving both hips and ankles successfully treated with steroids (no more information was available). Since the age of 60 she referred with skin lesions, not better specified which were treated with topical steroids. There was no history of face rush, Reynaud’s phenomenon or oral ulcers. There was no history of neurological or neuromuscular disorders.

**Laboratory work-up**

Routine blood tests including inflammation indexes, electrolytes, renal, liver and thyroid function, creatine kinase, glucose, vitamin B12, folic acid, hemoglobin level, platelet count, white blood cell count, prothrombin time and activated partial prothrombin time were all within the normal range.

Rheumatologic blood tests showed highly positive antinuclear antibodies (4.91 IU/mL, normal range 0-1 IU/mL) speckled pattern; high levels of anti-dsDNA antibodies (69.4 IU/mL, normal range 0-30 IU/mL); dRVTT screening 38.7 sec (normal range 0-1 sec).
range 0-38 sec); dRVVT ration 1.33 (normal range 0.80-1.30); serum complement C3 and C4 levels were slightly reduced (C3 = 85 mg/dL, normal 90-180 mg/dL; C4 = 9 mg/dL, normal range 10-40 mg/dL); ENA (anti-Sm, Sm/RNP, SSA, SSB, JO1, SCL-70 and ENA screening) were negative; aPL (IgG = 1.1 U/ml, IgM = 1.3 U/ml) and anticardiolipin antibodies (GPL 1.3 U/ml, MPL 1.6 U/ml) were normal. Lupus anticoagulant (PTT-LA), Protein C, Rheuma test, W-Rose test and immunoglobulin levels (IgG, IgA, IgM) were in the normal range.

A lumbar puncture revealed normal white cells count with an elevated protein level of 110 mg/dL (normal range 15-45 mg/dL). Glucose and chlorides levels were normal, same oligoclonal pattern in serum and cerebrospinal fluid (CSF) suggesting no intrathecal synthesis. S-IgG 1040 mg/dL, LCR-IgG 4.54 mg/dl (0.80-3.80); IgG index 0.82 (normal range < 0.70); Tourtellotte Index 6.39 (<3.30). PCR for HSV1, HSV2 and Adenovirus were negative. HIV serology was negative.

**MRI study**

Magnetic resonance (MR) scan was performed on a Signa Contour (General Electric, Milwaukee, IL, USA) 0.5 Tesla...
It has been estimated that TM can be the early manifestation of SLE in 29% and no improvement in 21%. On the contrary, at least 50% of patients with LM seem to have a poor prognosis. Although the final prognosis relies on different variables such as a prompt diagnosis, specific treatment strategies and the extent of the neurological involvement, previous reports showed that a rapid diagnosis and an early aggressive immunosuppressive therapy using high doses of corticosteroids and pulsed IV-CYC is associated with a satisfactory outcome only in TM. Still controversial for LM due to the paucity of published studies. Téllez-Zenteno et al commented that the outcome can be unfavorable in most cases even if an aggressive treatment with high dose corticosteroids and CYC is started. In fact, this drug-combination showed to be successful in only one reported case and a slow improvement was noted in another one out of the six described by Téllez-Zenteno.

Our patient showed a very good response to treatment and a final favorable outcome. Compared to other reported cases, the main difference relates to the combined use of synchronized plasmapheresis. Despite the paucity of data on therapeutic interventions in LM, it is plausible to speculate that early aggressive treatment strategies, using a combination of plasmapheresis and immunosuppressive agents, need to be considered in patients with LM. This is further supported by a few other cases characterized by a favorable outcome adopting early aggressive treatment strategies. Moreau et al described the first report of LM in a pregnant patient with SLE, promptly treated with corticosteroid and plasmapheresis with complete recovery. Lehnhardt et al described a case of LM and SLE-related aseptic meningitis in which only autologous hematopoietic stem cell transplantation was successful with no evidence for residual serological or neuroradiological activity of SLE. Mok et al reported the preliminary experience of the use of combined corticosteroid and mycophenolate mofetil, a relatively new immunosuppressive agent, in the treatment of SLE-related myelopathy, concluding that immunosuppressive treatments should be considered in some selected cases, especially if refractory to CYC.

Nonetheless, it is also tempting to speculate that the lack of aPL in our patient may represent an index of favorable prognosis. It has been suggested that patients with LM should always be
tested for aPL\textsuperscript{21}, it being possibly implicated in the pathogenetic processes of the LM itself. Further research is needed to clarify whether aPL may represent an index of poor response to treatment in patients with LM.

As to the peripheral nervous system (PNS) involvement in SLE patients, a Guillain-Barré syndrome, an autonomic neuropathy, mononeuropathies, plexopathies, and a sensorimotor polyneuropathy were reported\textsuperscript{9}. The PNS involvement is usually regarded as a rare complication of SLE, with prevalence rates ranging between 3\% and 27\% in various clinical series\textsuperscript{9-43}. The neuropathic process is usually modestly progressive over the time, with possible fluctuations and not necessarily irreversible\textsuperscript{44,45}. To the best of our knowledge, there is only one report of simultaneous SLE-related LM and peripheral neuropathy\textsuperscript{7}. In our patient, the favorable outcome was also found for PNS involvement with nerve conduction study follow-up demonstrating a progressive improvement over two years. In our opinion, these findings further support the hypothesis that patients with negative aPL may configure a particular clinical phenotype with a favorable prognosis.

In conclusion, LM represents a rare but serious and possibly life-threatening complication of SLE. Data on therapeutic strategies are still scanty as the identification of clinical and biological indexes for prognosis and response to treatment. We described a case of LM with associated polyneuropathy without aPL, which displayed a favorable outcome after aggressive immune-suppressive treatment. Further studies involving larger samples are warranted to develop standardized clinical protocols for therapy and prognosis.

REFERENCES


